title: Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice.
abstract: BACKGROUND
  Only few data are available on the efficacy of tigecycline in critically ill patients.
  
  
  METHODS
  This prospective, multicenter, non-interventional study investigated the efficacy and safety of tigecycline in hospitalized, severely ill patients with complicated intra-abdominal infections (cIAI) and/or complicated skin and soft tissue infections (cSSTI). Documentation included diagnosis, clinical findings, Acute Physiology and Chronic Health Evaluation II score, laboratory assessments, surgery, clinical outcomes, and adverse events.
  
  
  RESULTS
  Six hundred and fifty-six patients (mean Acute Physiology and Chronic Health Evaluation II score 19.1) with cIAI (41%), cSSTI (16%), multiple infection sites (13%) and/or other severe infections (31%) received tigecycline - 51% as monotherapy - due to failure of previous antibiotics (55%) or since resistant pathogens were suspected or proven (45%); clinical cure/improvement rates were 75, 82, 76 and 67% for cIAI, cSSTI, other severe infections and multiple infection sites, respectively. Drug-related adverse events occurred in 6.7% of patients.
  
  
  CONCLUSIONS
  The efficacy and safety of tigecycline was demonstrated in a population of severely ill patients with complicated infections.
authors.affiliation: Department of General, Visceral and Thoracic Surgery, Academic Hospital of Medical University Hannover, Peine, Germany. Christian.Eckmann @ klinikum-peine.de
authors.forename: Christian
authors.initials: C
authors.lastname: Eckmann
authors.forename: Wolfgang R
authors.initials: WR
authors.lastname: Heizmann
authors.forename: Eva
authors.initials: E
authors.lastname: Leitner
authors.forename: Christof
authors.initials: C
authors.lastname: von Eiff
authors.forename: Klaus-Friedrich
authors.initials: KF
authors.lastname: Bodmann
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004926:Escherichia coli / Q000472:pathogenicity; D005260:Female; D005858:Germany; D006801:Humans; D007239:Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies; D012720:Severity of Illness Index; D018461:Soft Tissue Infections / Q000188:drug therapy; D013207:Staphylococcal Skin Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000472:pathogenicity; D000078304:Tigecycline; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline